Meeting
2012 ASCO Annual Meeting
Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in 180 U.S. breast cancer (BC) patients.
Authors
Lisette Stork-Sloots
Agendia, Amsterdam, Netherlands
Lisette Stork-Sloots , Katharine Yao , Mary Turk , Karen Kaul , JoEllen Weaver , Femke De Snoo , Massimo Cristofanilli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 30, 2012 (suppl; abstr 577)
DOI
10.1200/jco.2012.30.15_suppl.577
Abstract #
577
Poster Bd #
6D
Abstract Disclosures
Similar Posters
Poster
2012 Breast Cancer Symposium
Molecular subtyping using MammaPrint and BluePrint as an outcome predictor in U.S. breast cancer (BC) patients.
First Author: Katharine Yao
Poster
2022 ASCO Annual Meeting
Identification of transcriptional changes with MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant chemotherapy.
First Author: Alice P. Chung
Poster
2013 Breast Cancer Symposium
Can Oncotype DX recurrence score (RS) be used in Luminal A and Luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective unicentric study in Spanish population.
First Author: Laura G. Estevez
Poster
2013 ASCO Annual Meeting
Impact of body mass index (BMI) on the prognosis of women with high-risk early breast cancer (BC) receiving adjuvant chemotherapy (CT).
First Author: Alessandra Gennari